tetano
Editor, Senior Moderator
Nat Commun
. 2022 Mar 31;13(1):1699.
doi: 10.1038/s41467-022-29219-2.
Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates
Vincent Pavot[SUP] #[/SUP][SUP] 1 [/SUP], Catherine Berry[SUP] #[/SUP][SUP] 1 [/SUP], Michael Kishko[SUP] 2 [/SUP], Natalie G Anosova[SUP] 2 [/SUP], Dean Huang[SUP] 2 [/SUP], Tim Tibbitts[SUP] 2 [/SUP], Alice Raillard[SUP] 1 [/SUP], Sylviane Gautheron[SUP] 1 [/SUP], Cindy Gutzeit[SUP] 3 [/SUP], Marguerite Koutsoukos[SUP] 4 [/SUP], Roman M Chicz[SUP] 2 [/SUP], Valerie Lecouturier[SUP] 5 [/SUP]
Affiliations
Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that partly evade neutralizing antibodies raises concerns of reduced vaccine effectiveness and increased infection. We previously demonstrated that the SARS-CoV-2 spike protein vaccine adjuvanted with AS03 (CoV2 preS dTM-AS03) elicits robust neutralizing antibody responses in naïve subjects. Here we show that, in macaques primed with mRNA or protein-based subunit vaccine candidates, one booster dose of CoV2 preS dTM-AS03 (monovalent D614 or B.1.351, or bivalent D614 + B.1.351 formulations), significantly boosts the pre-existing neutralizing antibodies against the parental strain from 177- to 370-fold. Importantly, the booster dose elicits high and persistent cross-neutralizing antibodies covering five former or current SARS-CoV-2 variants of concern (Alpha, Beta, Gamma, Delta and Omicron) and, unexpectedly, SARS-CoV-1. Interestingly, we show that the booster specifically increases the functional antibody responses as compared to the receptor binding domain (RBD)-specific responses. Our findings show that these vaccine candidates, when used as a booster, have the potential to offer cross-protection against a broad spectrum of variants. This has important implications for vaccine control of SARS-CoV-2 variants of concern and informs on the benefit of a booster with the vaccine candidates currently under evaluation in clinical trials.
. 2022 Mar 31;13(1):1699.
doi: 10.1038/s41467-022-29219-2.
Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates
Vincent Pavot[SUP] #[/SUP][SUP] 1 [/SUP], Catherine Berry[SUP] #[/SUP][SUP] 1 [/SUP], Michael Kishko[SUP] 2 [/SUP], Natalie G Anosova[SUP] 2 [/SUP], Dean Huang[SUP] 2 [/SUP], Tim Tibbitts[SUP] 2 [/SUP], Alice Raillard[SUP] 1 [/SUP], Sylviane Gautheron[SUP] 1 [/SUP], Cindy Gutzeit[SUP] 3 [/SUP], Marguerite Koutsoukos[SUP] 4 [/SUP], Roman M Chicz[SUP] 2 [/SUP], Valerie Lecouturier[SUP] 5 [/SUP]
Affiliations
- PMID: 35361754
- DOI: 10.1038/s41467-022-29219-2
Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that partly evade neutralizing antibodies raises concerns of reduced vaccine effectiveness and increased infection. We previously demonstrated that the SARS-CoV-2 spike protein vaccine adjuvanted with AS03 (CoV2 preS dTM-AS03) elicits robust neutralizing antibody responses in naïve subjects. Here we show that, in macaques primed with mRNA or protein-based subunit vaccine candidates, one booster dose of CoV2 preS dTM-AS03 (monovalent D614 or B.1.351, or bivalent D614 + B.1.351 formulations), significantly boosts the pre-existing neutralizing antibodies against the parental strain from 177- to 370-fold. Importantly, the booster dose elicits high and persistent cross-neutralizing antibodies covering five former or current SARS-CoV-2 variants of concern (Alpha, Beta, Gamma, Delta and Omicron) and, unexpectedly, SARS-CoV-1. Interestingly, we show that the booster specifically increases the functional antibody responses as compared to the receptor binding domain (RBD)-specific responses. Our findings show that these vaccine candidates, when used as a booster, have the potential to offer cross-protection against a broad spectrum of variants. This has important implications for vaccine control of SARS-CoV-2 variants of concern and informs on the benefit of a booster with the vaccine candidates currently under evaluation in clinical trials.